Case 2: Addressing Structural Racism in Medicine - Prevention and Care for Principal Populations - Video Modules - HIV Annual Update 2021 - HIV

Case 2: Impact of COVID-19 on HIV Care and Addressing Issues of Structural Racism in Medicine

In this on-demand webcast of a live roundtable, expert faculty consider the latest data on currently available and emerging PrEP options as they discuss how to tailor PrEP strategies for people at high risk for HIV and how advances in PrEP continue to be essential for addressing the unique prevention needs of each person. Then the faculty panel explores the effects of the COVID-19 pandemic on HIV care and how infectious disease healthcare professionals can work toward addressing the complex issues of structural racism in medicine that were underscored by COVID-19.

Babafemi Taiwo, MBBS
Program Director

Daniel R. Kuritzkes, MD

Darcy Wooten, MD

Released: October 26, 2021

Information on this Educational Activity

Program Director

Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees from Gilead Sciences, Merck, and ViiV and funds for research support from Janssen.

Faculty

Daniel R. Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD, has disclosed that he has received funds for research support rom Atea, Gilead Sciences, Merck, Novartis, and ViiV and consulting fees from Abpro, Atea, Decoy, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Rigel, and ViiV.

Darcy Wooten, MD

Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California

Darcy Wooten, MD, has no relevant conflicts of interest to report.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Sarah Anderson, PharmD

Scientific Director

Sarah L. Anderson, PharmD, BCACP, BCPS, FASHP, FCCP, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Medical Minute on Key Decisions in HIV Care: Treating HIV/HCV Coinfection

View Multimedia

Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.